Literature DB >> 15125924

Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.

Brian H Heasley1, Renata Jarosz, Kevin R Lynch, Timothy L Macdonald.   

Abstract

A recently reported dual LPA1/LPA3 receptor antagonist (VPC12249, 1) has been modified herein so as to optimize potency and selectivity at LPA receptors. Compounds containing variation in the acyl lipid chain and linker region have been synthesized and screened for activity at individual LPA receptors. LPA1-selective (14b) and LPA3-selective (10g,m) compounds of modest potency have been discovered. Additionally, 2-pyridyl derivative 10t exhibits a Ki value of 18 nM at the LPA1 receptor and is significantly more potent than 1 at the LPA3 receptor. This paper describes the synthetic methods, biological evaluation, and structure-activity relationships (SARs) of LPA receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15125924     DOI: 10.1016/j.bmcl.2004.03.076

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.

Authors:  Peng Cui; Jose L Tomsig; William F McCalmont; Sangderk Lee; Christopher J Becker; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

4.  2D binary QSAR modeling of LPA3 receptor antagonism.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2010-03-07       Impact factor: 2.518

5.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

6.  Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase.

Authors:  Arindam Talukdar; Ekaterina Morgunova; Jianxin Duan; Winfried Meining; Nicolas Foloppe; Lennart Nilsson; Adelbert Bacher; Boris Illarionov; Markus Fischer; Rudolf Ladenstein; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2010-04-08       Impact factor: 3.641

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 8.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

Authors:  Yasuyuki Kihara; Michael Maceyka; Sarah Spiegel; Jerold Chun
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

9.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

10.  LPA Stimulates the Phosphorylation of p130Cas via Gαi2 in Ovarian Cancer Cells.

Authors:  Jeremy D Ward; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.